Daily requirement for pyridoxine supplements in chronic renal failure  by Kopple, Joel D. et al.
Kidney International, Vol. 19 (1981), pp. 694—704
Daily requirement for pyridoxine supplements in chronic
renal failure
JOEL D. KOPPLE, KENNETH MERCURIO, MICHAEL J. BLUMENKRANTZ, MICHAEL R.
JONES, JULIA TALLOS, CHARLOTTE ROBERTS, BETTY CARD, ROBERT SALTZMAN,
DENNIS A. CASCIATO, and MARIAN E. SWENDSEID
Medical and Research Services, Veterans Administration Wadsworth Medical Center, and Schools of Medicine and
Public Health, University of California at Los Angeles, Los Angeles, California
Daily requirement for pyridoxine supplements in chronic renal
failure. Vitamin B6 deficiency was evaluated in 37 patients with
chronic renal failure and in 71 patients undergoing maintenance
hemodialysis (HD) or intermittent peritoneal dialysis (PD). Vita-
min B6 deficiency was assessed by the in vitro activity of
erythrocyte glutamic pyruvic transaminase (EGPT), without
(basal) and with (stimulated) the addition of pyridoxal-5-phos-
phate to the assay, and the EGPT index (stimulated activity
basal activity). Basal and stimulated EGPT activities were below
normal in the HD patients, and the EGPT index was increased in
each group of patients, indicating vitamin B6 deficiency. Supple-
mental pyridoxine hydrochloride was given to 30 HD patients
who received 1.25 to 50 mg/day (37 studies), 6 PD patients who
were given 1.25 or 2.5 mglday (7 studies), and 8 nondialyzed
patients with mild to severe renal failure who received 2.5 mg/
day. In all HD patients, 10 or 50 mg/day of pyridoxine hydrochlo-
ride rapidly corrected the abnormal EGPT index and maintained
normal values; with supplements of 5.0 mg/day or less, the index
was often abnormal, particularly in those who were septic or
taking pyridoxine antagonists. In PD patients and nondialyzed
patients with renal failure, 2.5 mg/day of pyridoxine hydrochlo-
ride was inadequate to correct rapidly the abnormal index in all
patients. These findings suggest that HD patients should receive
10mg/day of supplemental pyridoxine hydrochloride (8.2 mg/day
pyridoxine). PD patients and patients with chronic renal failure
should receive about 5.0 mg/day of supplemental pyridoxine
hydrochloride (4.1 mg/day pyridoxine). When sepsis intervenes
or vitamin B6 antagonists are taken, 10 mg/day of pyridoxine
hydrochloride may be a safer supplement for all patients.
Besoin journalier en supplements de pyridoxine au cours de
l'insuffisance renale chronique. Le deficit en vitamine B6 a été
évalué chez 37 malades atteints d'insuffisance rénale chronique
et 71 malades soumis a l'hémodialyse chronique (HD) ou a Ia
dialyse péritonéale intermittente (PD). Le deficit en vitamine B6
a etC èvalué par l'activité in vitro de la transaminase glutamo-
pyruvique erythrocytaire (EGPT) avant (valeur basale) et aprCs
(valeur stimulée) addition de pyridoxal-5-phosphate ala reaction
et par l'index d'EGPT (activitC stimulée/activitC basale). Les
activités basale et stimulée de EGPT étaient inférieures a Ia
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normale chez les malades en HD et l'index d'EGPT Ctait
augmenté dans chaque groupe de malades, ce qui indique un
deficit en vitamine B6. Un supplement de pyridoxine hydrochlo-
ride a Cté donnC a 30 malades HD qui ont recu 1,25 a so mg/jour
(37 etudes), a 6 malades en PD qui ont recu 1,25 ou 2,5 mg/jour (7
etudes), et 8 malades non dialyses, atteints d'insuffisance rénale
moyenne ou sévère qui ont recu 2,5 mg/jour. Chez tous les
malades en HD, 10 ou 50 mg/jour de pyridoxine hydrochloride
ont rapidement corrigé l'index anormal d'EGPT et maintenu des
valeurs normales. Avec des supplements de 5 mg/jour, ou moms,
l'index Ctait souvent anormal, particuliérement chez les malades
infectés ou qui prenaient des antagonistes de La pyridoxine. Chez
les malades en PD et les malades en insuffisance rénale non
dialyses, 2,5 mg/jour de pyridoxine hydrochloride n'ont pas suffi
a corriger rapidement les anomalies de l'index chez tous les
malades. Ces constatations suggérent que les malades en HD
devraient recevoir 10 mg/jour de supplement de pyridoxine
hydrochloride (8,2 mg/jour de pyridoxine). Les malades en PD et
les malades en insuffisance rénale chronique devraient recevoir
environ 5,0 mg/jour de pyridoxine hydrochloride (4,1 mg/jour de
pyridoxine). S'il existe une infection ou si des antagonistes de la
vitamine B6 sont pris, 10 mg/jour de pyridoxine hydrochloride
sont plus adCquats chez tous les malades.
Several reports suggest that many nondialyzed
patients with chronic uremia and patients undergo-
ing maintenance hemodialysis have evidence of
vitamin B6 deficiency [1—71. The data supporting
these observations include low B6 cofactor satura-
tion of glutamic oxaloacetic transaminase and glu-
tamic pyruvic transaminase in red cells [3—5, 7], and
decreased plasma concentrations of pyridoxal-5-
phosphate [1, 41. In addition, many patients have a
low serum activity of glutamic oxaloacetic transa-
minase [2, 6] and manifest clinical signs similar to
those present in vitamin B6 deficiency [4]. Several
studies indicate that in renal failure, vitamin B6
deficiency can be successfully treated with large
doses of supplemental pyridoxine hydrochloride, 25
to 300 mg/day [3, 7, 81. Despite evidence for an
Pyridoxine requirement in renal failure
Table 1. Characteristics of subjects
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N
No. of
men
Agea
years
Serum creatininea
mg/dl
Duration of dialysis
therapy
months
Normal 17 14 39 16 — —
Chronic renal failure 37 34 54 6.8 4.0 —
Peritoneal dialysis 16 16 54 13C 18.3 37b, 5.0 (0 to 18)
Hemodialysis 55 53 49 1OC 14.5 40b, f 23.1 (4 to 87)
ayalues are the means SD.
bValues obtained at beginning of a dialysis treatment
C. different from normal, P < 0.01, P < 0.001, respectively.' Significantly different from chronic renal failure P < 0.05, P < 0.001, respectively.
Significant1y different from peritoneal dialysis, P < 0.01.
increased requirement for vitamin B6 in uremia,
there are no data concerning the daily requirement
for pyridoxine hydrochloride. We therefore admin-
istered different doses of pyridoxine to nondialyzed
patients with mild to severe chronic renal failure
and patients undergoing maintenance hemodialysis
or intermittent peritoneal dialysis to determine the
minimum daily supplement that will prevent and
correct vitamin B6 deficiency. The results indicate
that in adults, the supplemental pyridoxine that
ensures correction of vitamin B6 deficiency is about
5 mg/day for nondialyzed patients with chronic
renal failure and patients undergoing intermittent
peritoneal dialysis and about 10 mg/day for patients
receiving maintenance hemodialysis and for pa-
tients who are septic or taking pyridoxine antago-
nists.
Methods
Assessment of vitamin B6 deficiency. Two sepa-
rate investigations were carried out. In the first
study, vitamin B6 status was assessed in 17 normal
subjects, 37 nondialyzed patients with mild, moder-
ate, or severe renal failure, 16 patients undergoing
chronic intermittent peritoneal dialysis, and 55 pa-
tients receiving maintenance hemodialysis. Twen-
ty-two of the hemodialysis patients were studied
before and after a single dialysis treatment. Prior to
blood drawing, it was ascertained that no patient
was taking a vitamin B6 preparation. The nondia-
lyzed patients with chronic renal failure were subdi-
vided into those with mild renal failure (serum
creatinine concentration 2.9 0.5 SD mg/dl; range,
2.1 to 3.5; N=9), moderate renal failure (serum
creatinine concentration, 2.9 [SD] 0.5 mg/dl;
range, 2.1 to 3.5; N= 9), moderate renal failure
(serum creatinine, 4.9 0.8 mg/dl; range, 3.6 to
5.7; (N=9), and severe renal failure (serum creati-
nine, 10.2 3.4 mg/dl; range, 6.2 to 18.2; N= 16).
In 3 patients with chronic renal failure, serum
creatinine concentrations were not available at the
time of blood drawing.
Assessment of pyridoxine requirements. In the
second experiment, the daily requirement for sup-
plemental pyridoxine was evaluated in 8 nondia-
lyzed patients with chronic renal failure, 6 patients
undergoing intermittent peritoneal dialysis (7 stud-
ies), and 30 patients receiving maintenance hemo-
dialysis (37 studies). One hemodialysis patient was
studied with three different doses of pyridoxine
hydrochloride; several other patients were studied
with two different doses. Characteristics of the
subjects are shown in Table 1.
The vitamin B6 supplement was given as pyridox-
me hydrochloride, which is composed of about 82%
pyridoxine. The quantities of pyridoxine adminis-
tered to the hemodialysis patients were as follows:
41 mg/day, 7 patients; 8.2 mg/day, 5 patients; 4.1
mg/day, 11 patients; 2.1 mg/day, 11 patients; 1.0
mg/day, 3 patients. Patients undergoing intermittent
peritoneal dialysis were given either 2.1 mg/day (6
patients) or 1.0 mg/day (1 patient) of pyridoxine.
Patients with chronic renal failure were adminis-
tered 2.1 mg/day of the supplement; their mean
serum creatinine concentration was 5.0 mg/dl
(range, 2.8 to 8.6).
Prior to beginning pyridoxine supplementation,
blood was drawn from each patient on one to three
separate occasions for measurement of erythrocyte
glutamic pyruvic transaminase (EGPT) activity
(vide infra). Patients were then prescribed a given
dose of pyridoxine hydrochloride for 21 to over 250
days. Patients were instructed to take their dose of
pyridoxine at the same time each day. On days
when patients received a hemodialysis treatment, a
nurse gave the patient the pyridoxine dose at the
end of the dialysis procedure. Patients were moni-
tored frequently for EGPT activity and for their
adherence to vitamin therapy. Compliance was
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stimulated EGPT activity
basal EGPT activity
assessed by direct questioning of the patient and by (pH, 7.4) to each tube with room lights off and
the frequency with which patients requested refills, incubated each tube at 37° C for exactly 40 mm with
Those few patients who did not comply were with- shaking. We added 0.1 ml of 50% TCA to the basal
drawn from the study. and stimulated tubes. Tubes were allowed to come
All patients were clinically stable at the onset of to room temperature, 1.0 ml of 25 mri 2,4-dinitro-
the study, but some developed illnesses during the phenyihydrazine (DNP, Sigma) in 2.4 N hydrochlo-
study. During periods when patients were hospital- nc acid was added, and tubes were vortex mixed
ized, they continued to receive pyridoxine. immediately. The 2,4-dinitrophenylhydrazone of
Pyridoxine hydrochloride tablets, 10 and 25 mg, pyruvate was extracted with 2 ml of toluene, and
were obtained from Stanlabs, Inc. (Portland, Or- 3.0 ml of alcoholic potassium hydroxide (2.5 g of
egon). Patients receiving the 5.0- or 50-mg doses potassium hydroxide per deciliter of 95% ethanol)
took two 2.5 or 25 mg tablets each day, respective- was added to 1.0 ml of the extract. After the tubes
ly. The 1.25- and 2.5-mg pyridoxine hydrochloride were mixed, absorbance was measured on a spec-
capsules were prepared in the manufacturing phar- trophotometer (Gilford, model 240) at 525 nm.
macy at VA Wadsworth Medical Center from pyri- Assays were usually performed in triplicate.
doxine hydrochloride obtained from Pfizer Labora- Basal and stimulated (pyridoxal-5-phosphate add-
tories (New York, New York). ed) EGPT activity was calculated as micrograms of
Preparation of hemolysates. Blood was usually pyruvate formed per milliliter of packed erythro-
obtained between 8:00 and 9:00 A.M. In hemodialy- cytes per hour. EGPT index was calculated as the
sis patients, blood was drawn immediately before ratio of stimulated activity to basal activity as
and, in 22 cases, at the end of a dialysis. Heparin- follows:
ized blood was immediately centrifuged at 3000 rpm
for 15 mm. The plasma and buffy coat were re-
moved quickly, and a volume of saline equal to that
of the original plasma was mixed with the packed
•EGPT index =
cells. The tube was recentrifuged; saline was re-
moved; and a volume of water twice that of the An EGPT index of 1.25 or less was considered
packed red cells was added to induce hemolysis. normal.
The contents were frozen at —40° C and analyzed Confirmation of pyridoxine content of tablets.
within 2 days of collection. Samples of 10 and 25 mg of pyridoxine hydrochlo-
Erythrocyte glutamic pyruvic transaminase ride tablets and 2.5-mg capsules were selected at(EGPT) activity assay and EGPT index. EGPT random for analysis. Tablets and capsules were
activity was assayed in the hemolysate by a method dissolved in 10 ml of water and measured with a
similar to that of Tonhazy, White, and Umbreit [91 liquid chromatograph (Waters Associates, model
as modified by Cinnamon and Beaton 1110]. We ALC-202) with a p.Bondapak-C18 column. Each
added 0.5 ml of hemolysate, 0.6 ml of 0.11 M dibasic solution was analysed in triplicate. The assay was
potassium phosphate (pH, 7.4), and 0.1 ml of 50% calibrated with a sample of pyridoxine hydrochlo-
w/v trichioroacetic acid (TCA) to a tube designated ride (Sigma). Recovery of pyridoxine hydrochloride
as the blank; and we added 0.5 ml of hemolysate from the tablets was 95 to 105% of the expected
and 0.6 ml or 0.5 ml of the dibasic potassium value in all cases.
phosphate buffer, respectively, to tubes designated Informed consent was obtained in all subjects.
as basal activity (no pyridoxal phosphate added) or Statistics were performed with Student's t test and
stimulated activity (pyridoxal phosphate added). linear regression analysis.
Standard tubes with 20, 40, and 60 pg/ml sodium
pyruvate (Calbiochem) were prepared with 1.0 ml Results
of the standard and with the same procedure as that Basal EGPT activity, EGPT activity after stimu-
used with the blank. The tubes were vortex mixed, lation with pyridoxal phosphate, and the EGPT
and 0.1 ml of 4.2 mri pyridoxal-5-phosphate (Cal- index are shown in Table 2. The basal and stimulat-
biochem) in phosphate butter (pH, 7.4) was added ed EGPT activities tended to be lowest in the
to the stimulated tube in a darkened room. Tubes hemodialysis patients and were each significantly
were incubated with shaking at 37° C for 60 mm. We less than the values in the normal subjects, the
added 0.5 ml of 0.2 M DL-alanine and 0.04 M a- individuals with mild renal failure, and the total
ketoglutarate (Calbiochem) in phosphate buffer group of nondialyzed patients with chronic renal
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Table 2. Erythrocyte glutamic pyruvic transaminase (EGPT) activity and indices and protein and vitamin B intake in normal
controls, and in patients with chronic renal failure and those on maintenance hemodialysis or peritoneal dialysisa
Serum
creatinine
mg/dI
(range) N
EGPT activity
without PLP
EGPT activity
with PLP EGPT index
No. with
EGPT index
>l.25l
Protein
intake
giday
Vitamin B6
intakecmg/day
(no.)
Normal controls 17 374 140 437 167 1.16 0.06 0 (0) — —
Chronic renal
failure
Mild 2.9
(2.1 to 3.5) 9 384 146 461 l47 1.23 o.o9 4 (44) 84 18 2.2 0.8 (6)
Moderate 4.9
(3.6 to 5.7) 9 280 104 356 110 1.30 011h 6(66) 76 10 2.0 1.3 (6)
Severe
Total"
10.2
(6.2 to 18.2) 16
37
293 165
315 l47
363 193
390 163k
1.28 O.l9
1.27 0.l5 I. k
6 (37)
18 (49)
70 7
78 13
1.2 0.5 (7)
1.7 0.9 (21)
Peritoneal
dialysis 16 291 216 365 205 1.41 0.27" 12(75) 97 11 1.6 0.3(8)
Hemodialysisc
Total 55 238 120" 317 129g 1.44 O.39 36 (65) 70 15 1.4 0.4 (10)
Predialysis
Postdialysis
22
22
209 116"
227 119g
317 l38
318 l34
1.63 0.32"
1.53 0.38"
21(95)
19(86)
—
—
—
—
aValues are the means SD. EGPT activity is expressed in micrograms of pyruvate per milliliter red cell hemolysate per hour. PLP re-
fers to pyridoxal-5-phosphate.
blndicates the number and percentage of subjects with EGPT index of 1.26 or greater.
cRefers to vitamin B6 ingested in foods; parentheses indicate number of patients evaluated.
dIncludes 3 patients with chronic renal failure for whom serum creatinine levels were not available at the time of blood drawing
eTotal and predialysis values were all obtained immediately prior to the onset of a dialysis treatment. All patients for whom predialysis
values were obtained also had postdialysis values analyzed.
f. S. from normal subjects, P < 0.05, P < 0.01, P < 0.001, respectively.
"Differs from all hemodialysis patients combined, P < 0.02, P < 0.01, respectively.
kDiffers from peritoneal dialysis patients, P < 0.05.
failure. There were no significant differences in
these values among the normal, chronic renal fail-
ure, and peritoneal dialysis groups.
None of the normal subjects had an abnormally
high EGPT index (>1.25). The EGPT index was
significantly greater than normal in each group of
nondialyzed patients with chronic renal failure and
in the peritoneal dialysis and hemodialysis patients.
The mean EGPT index and the percentage of pa-
tients with abnormally high EGPT indices tended to
increase with the severity of renal failure. The
EGPT index was greater in the peritoneal dialysis
and the hemodialysis patients as compared with the
patients with chronic renal failure. There was no
change in the EGPT activities or index between the
beginning and end of hemodialysis.
Because the age of the normal subjects was less
than that of the patients with renal failure (Table 1),
the EGPT data were reevaluated after exclusion of
the 7 youngest normal subjects. The mean age of
the remaining 10 normal controls was 47 13
years, which was not significantly different from
any group of patients with renal failure. In these 10
normal individuals, the basal and stimulated EGPT
activities were 393 165 and 457 201 pmoles of
pyruvate per milliliter of red cell hemolysate per
hour, respectively. These values were significantly
higher than those in the hemodialysis patients (P <
0.001 and P < 0.01, respectively). The EGPT index
in the 10 normal subjects was 1.15 0.07, which
was significantly less than that in the patients with
mild and moderate failure, the total group of non-
dialyzed patients with renal failure, and the perito-
neal dialysis and hemodialysis patients. The EGPT
index in the normal subjects did not differ from the
nondialyzed patients with severe renal failure (P <
0.10).
The basal and stimulated EGPT activities and the
EGPT index did not correlate with age in any group
individually or in all four groups combined.
Dietary intake of pyridoxine hydrochloride. The
vitamin B6 intake from food was calculated from
dietary interviews in 39 patients at the time of initial
assessment for vitamin B6 deficiency (Table 2). The
mean vitamin B6 intake in the patients with severe
renal failure and those undergoing dialysis was less
than the National Academy of Sciences recom-
mended daily allowance of 2.0 to 2.2 mg for non-
pregnant, nonlactating adults [11]. In the patients
with mild or moderate renal failure, there were
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several patients with intakes below the recommend-
ed daily allowance. The relation between vitamin
B6 intake and the daily protein intake was not quite
significant (r = 0.363, P < 0.06). Rather, those
patients ingesting foods fortified with vitamins in-
cluding B6, especially the prepackaged cereals,
tended to have the highest B6 intakes. There was no
correlation between dietary B6 intake and basal or
stimulated EGPT activities or the EGPT index in
the chronic renal failure and/or dialysis patients.
During the studies with supplemental pyridoxine
hydrochloride, the dietary vitamin B6 intake, mea-
sured periodically in dialysis patients, averaged 1.5
0.4 mg/day.
Supplementation with pyridoxine hydrochloride.
The results of giving hemodialysis patients supple-
mental pyridoxine hydrochloride in doses of 1.25,
2.5, 5.0, 10.0, and 50 mg/day are shown in Figs. 1
through 5. In all figures, data at zero time indicate
the mean of one to three values obtained before
pyridoxine hydrochloride supplementation was be-
gun. Prior to supplementation, 4 of the 7 hemodialy-
sis patients who received 50 mg/day of pyridoxine
hydrochloride had an abnormal EGPT index (Fig.
1). In I person, pretreatment values were not avail-
able. In the other 6 patients, the EGPT index fell
rapidly to very low levels; also, in 6 patients the
EGPT index decreased to 1.00 or less, indicating
that the addition of pyridoxal phosphate to the
assay did not enhance EGPT activity. After discon-
tinuing pyridoxine hydrochloride, the EGPT index
rose in all patients, and within 10 days it became
abnormal in 2 individuals.
Of the 5 hemodialysis patients receiving 10
mg/day of pyridoxine hydrochloride, 3 had abnor-
mal EGPT indices before treatment, and in an
additional patient values were borderline abnormal
that is, 1.25 (Fig. 2). The EGPT index fell to normal
in each patient within 7 days of therapy and contin-
ued to decrease, although not as markedly as it did
with the 50-mg/day dose. After the pyridoxine sup-
plement was stopped, the EGPT index rose in each
patient.
Eleven hemodialysis patients were given pyri-
doxine hydrochloride at 5.0 mg/day (Fig. 3) and in
most patients the index quickly became normal. In
1 patient, however, the EGPT index was still abnor-
mal after 25 days of therapy, and in 6 patients, the
EGPT index became abnormal again while they
continued to receive supplementation. Several of
these patients differed from most of the others in
that they were either very catabolic (3 patients) or
were taking the pyridoxine antagonists, hydralazine
or estrogens [121. Two of these patients died of
infection and other complications of hemodialysis.
It is of interest that one patient who was receiving
•2.34
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Fig. 1. Response of the erythrocyte glutamic pyruvic transamin-
ase (EGPT) index in 7 hemodialysis patients receiving 50 mg/day
of supplemental pyridoxine hydrochloride. The measured EGPT
index is indicated by circles. Lines connect data from the same
patient. Solid lines represent the time when pyridoxine hydro-
chloride was administered; broken lines indicate the period after
the supplement was discontinued. Data at zero time represent
the mean of one to three values obtained before the supplement
was begun. The heavy horizontal line represents the upper limit
of normal EGPT index (that is, 1.25).
20 40 60 80
>(
0)
-aC
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Time, days
Fig. 2. Response of EGPT index in 5 hemodialysis patients
receiving 10 mg/day of supplemental pyridoxine hydrochloride.
Symbols are described in the legend to Fig. 1.
20 40
aI—0
LU
Fig. 4. Response of EGPT index in 11
hemodialysis patients receiving 2.5 mg/day of
pyridoxine hydrochloride. Note the break in the
time scale after day 80. Other symbols are as in
Fig. 1.
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Fig. 3. Response of EGPT index in 11 hemodialysis patients receiving 5.0 mg/day ofpyridoxine hydrochloride. Note the break in the time
scale after day 100. Other symbols are the same as in Fig. 1.
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hydralazine was a very large man (118 kg), which
might also have increased his pyridoxine require-
ment.
Eleven hemodialysis patients were given 2.5
mg/day of pyridoxine hydrochloride (Fig. 4). The
EGPT index decreased in all patients, but in 5
patients, it continued to be intermittently abnormal.
Three hemodialysis patients received pyridoxine,
1.25 mg/day (Fig. 5). The EGPT index became
S
normal in all 3 patients, but subsequently became
abnormal in 1. The course of a single peritoneal
dialysis patient who received 1.25 mg/day of pyri-
doxine hydrochloride for 78 days is also shown Fig.
5. His EGPT index never became normal.
Six patients undergoing intermittent peritoneal
dialysis were given 2.5 mg/day of supplemental
pyridoxine hydrochloride (Fig. 6). The EGPT index
became normal in each patient. But, in one patient,
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0 20 40 60 240
Fig. 5. Response of EGPT index in 3 hemodialysis
patients (circles) and I patient undergoing
intermittent peritoneal dialysis (crossed lines) fed
1.25 mg/day of supplemental pyridoxine
hydrochloride. Note the change in time scale after
day 80. Other symbols are described in the legend
to Fig. 1.
Fig. 6. Response of EGPT index in 6 patients
undergoing intermittent peritoneal dialysis
who were receiving 2.5 mg/day of pyridoxine
hydrochloride. Note the change in time scale after
day 80. Other symbols are described in the legend
to Fig. 1.
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the index did not become normal until he had
received the supplement for over 36 days.
Eight patients with chronic renal failure also
received supplemental pyridoxine hydrochloride,
2.5 mg/day (Fig.7). The EGPT index fell in each
patient and became normal in all patients by about
40 days. But, in 3 patients, the index became
abnormal intermittently with continued therapy.
When patients received the pyridoxine hydro-
chloride supplement, both the basal and stimulated
EGPT activity increased. This is shown in Fig. 8,
where the mean values are shown fOr basal and
stimulated EGPT activities in hemodialysis patients
receiving 1.25, 2.5, 5.0, 10.0, and 50.0 mg/day of
pyridoxine hydrochloride. It is apparent that both
basal and stimulated EGPT activities rose progres-
sively as long as supplementation was given. In
general, the greater the daily dose, the higher or
more rapid the rise in EGPT activity. With pyridox-
me supplementation, the basal EGPT activity tend-
ed to rise more than the stimulated activity, and,
hence, the EGPT index fell. As a rule, the EGPT
index fell more rapidly and to a greater extent with
the larger supplements of pyridoxine hydrochloride
(Figs. 1 through 7). With discontinuation of these
doses, the basal and stimulated EGPT activities
stabilized and then began to fall. The basal EGPT
activity often fell more rapidly, and, hence, the rise
in EGPT index occurred more quickly than did the
fall in stimulated EGPT activity.
Discussion
This investigation of the need for pyridoxine
supplements was undertaken because there is sub-
stantial evidence that vitamin B6 deficiency is com-
mon in patients with chronic renal failure [1—7]. In
the present study, there was a high incidence of
vitamin B6 deficiency as indicated by an elevated
EGPT index in patients with mild, moderate, and
severe chronic renal failure and in patients undergo-
ing maintenance peritoneal dialysis and hemodialy-
sis. In addition, patients undergoing hemodialysis
often had abnormally low basal and stimulated
EGPT activities.
These findings are similar to those of Mackenzie
et al, who reported low concentrations of serum
vitamin B6, measured by microbiological assay in
hemodialysis patients [1]. Also, in nondialyzed
chronically uremic patients and in hemodialysis
patients, Dobbelstein et a! found a high erythrocyte
glutamic oxaloacetic transaminase (EGOT) index,
another indicator of vitamin B6 deficiency [31.
Stone, Warnock, and Wagner reported a low plas-
ma pyridoxal-5-phosphate concentration and glu-
tamic oxaloacetic transaminase activity and a de-
creased stimulated EGOT activity in nondialyzed
patients with chronic uremia, which indicate vita-
min B6 deficiency [4]. As expected, these investiga-
tors also found an increased EGOT index in the
patients with chronic renal failure. But, the index
was reduced in their hemodialysis patients. Kleiner
et al also found low basal EGOT activity in hemodi-
alysis patients [7]; but, the EGOT index was nor-
mal. Both of the latter groups of investigators
concluded that the small increment in EGOT activi-
ty after stimulation with pyridoxal-5-phosphate was
due to a low quantity of apoenzyme [4, 7].
The present study indicates that vitamin B6 defi-
ciency, as determined by an abnormally high EGPT
index, can be corrected rapidly in all hemodialysis
patients with a daily supplement of either 10 mg or
50 mg of pyridoxine hydrochloride, which is equiv-
alent to 8.2mg or 41 mg of pyridoxine, respectively.
Administration of 1.25, 2.5, or 5.0 mg/day of pyri-
doxine hydrochloride corrected the abnormal
EGPT index in some but not all hemodialysis pa-
tients. Moreover, at these lower doses, when the
EGPT index did become normal, it often did so
after many days or weeks; in some patients the
index fluctuated between normal and abnormal
1.40
1.00
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Fig. 7. Response of EGPT index in 8 nondialyzed
patients with mild, moderate, or severe renal
failure who were receiving 2.5 ,ng/day of
supplemental pyridoxine hydrochloride. Note the
change in time scale after day 80. Other symbols
are described in the legend to Fig. I.
Time, days
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•—. With PLP
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————
Without PLP
Pyridoxine discontinued
1.25 mg 2.5 mg
0 30 60
ITT/
0 25 50 0 30 60 90
Time, days
Fig. 8. Response of basal (open circles) and stimulated (closed circles) EGFT activity in hemodialysis patients fed supplemental
pyridoxine hydrochloride in doses of 1.25, 2.5, 5.0, 10, and 50 mg/day. The data were obtained from the same hemodialysis patients
referred to in Fig. 1 through 5. The vlaues shown at zero time were obtained before the supplement was given. Solid lines indicate the
time when pyridoxjne hydrochloride was given; broken lines represent the period after the supplement was discontinued. For each
dosage, the circles represent the mean of values obtained from the patients within 5 days of the time indicated in the figure. Brackets
indicate the mean SD. The two circles without brackets indicate data that were obtained from only 1 patient.
values. It is of interest that most of the hemodialysis
patients whose EGPT index did not become perma-
nently normal with the 5.0-mg/day supplement were
either severely ill with sepsis or were taking medi-
cines that antagonized the effects of vitamin B6 [12].
Because infection and the use of vitamin B6 antago-
nists (for example, hydralazine, isoniazid, estro-
gens [13—15]) are common in renal failure, we sug-
gest that the pyridoxine supplement for all hemodia-
lysis patients that will correct and maintain a
normal EGPT index is about 8.2 mg/day.
These data are consistent with those of others
who gave hemodialysis patients 25 to 300 mg/day of
supplemental pyridoxine hydrochloride and cor-
rected vitamin B6 deficiency [3, 7, 8]. But, none of
these latter studies demonstrated a minimum daily
intake below which vitamin B6 deficiency was not
always corrected.
Although the EGPT index became normal in the 6
patients undergoing intermittent peritoneal dialysis
who received 2.5 mg/day of pyridoxine hydrochlo-
ride (Fig. 6), 1 patient responded slowly. Also, in 3
of the 8 patients with chronic renal failure who were
not receiving dialysis therapy, the EGPT index
fluctuated and was occasionally abnormally high
(Fig. 7). Moreover, in both the peritoneal dialysis
patients and the nondialyzed patients with renal
failure who were receiving 2.5 mg/day, the EGPT
indices, even when normal, tended to be rather
high. Considering the relatively small number of
patients studied, it would seem appropriate to rec-
ommend a daily supplement of pyridoxine hydro-
chloride, 5.0 mg/day, for both peritoneal dialysis
and chronic renal failure patients. If catabolic ill-
ness, such as sepsis, supervenes or if medicines that
antagonize vitamin B6 are taken, it is probably safer
to administer 10 mg/day of the supplement to these
patients.
We stress that the foregoing recommended in-
takes for chronic renal failure patients are for a
supplement to their average estimated vitamin B6
intake from food of about 1.2 to 2.2 mg/day. Also,
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for three reasons, no distinction has been made
between the pyridoxine requirement for repletion
and for maintenance. First, in these patients, the
highest pyridoxine hydrochloride supplement
which did not uniformly correct deficiency was
often associated with episodes where a normal
EGPT index became abnormal (Figs. 3 and 7).
Second, in most clinical settings, it is not easy to
obtain the measurements to assess vitamin B6 defi-
ciency. In these circumstances, it is probably safer
to treat the patient as if he were deficient. Third,
since intercurrent illness and prescription of medi-
cines that antagonize vitamin B6 are common in
renal failure, it may be safer to prescribe a dose of
pyridoxine hydrochloride that will correct or pre-
vent vitamin B6 deficiency under these conditions.
The recommended daily intake of pyridoxine for the
renal failure and maintenance dialysis patients is so
great that is unlikely that most of these patients will
consistently receive this quantity from foods.
Hence, it is suggested that the additional pyridoxine
required by such patients (that is, 4.1 to 8.2 mg/day)
be administered in tablets or capsules.
The steep rise in stimulated EGPT activity during
administration of pyridoxine hydrochloride and the
rapid decrease after discontinuing the supplement
suggest that pyridoxine hydrochloride may affect
the EGPT apoenzyme [16]. Kominami et al de-
scribed a protease in rat small intestine and skeletal
muscle that splits the apoprotein of pyridoxal en-
zymes [17]. They also found that pyridoxal protects
against this protease. Hence, it is possible that
pyridoxine hydrochloride administration decreases
the rate of degradation of the EGPT apoenzyme in
patients with renal failure.
It is puzzling that many of the patients who had
only a mild or moderate decrease in GFR had
evidence for vitamin B6 deficiency (Table 2). More-
over, their dietary intake of vitamin B6 was close to
the recommended daily allowance [11]. These con-
siderations suggest that in renal failure factors
other than uremic toxins or deficient intake cause
vitamin B6 deficiency. Spannuth et al suggest that
there is increased plasma clearance of pyridoxine in
patients with uremia [18]. But, it was not clear
whether these patients had vitamin B6 deficiency
and whether such deficiency in itself can increase
pyridoxine clearance. It is possible that the intact
kidney may be necessary for normal metabolism of
vitamin B6 and that even in mild renal failure the
parenchymal damage may impair this function.
Medicines that impair vitamin B6 action could also
contribute to vitamin B6 deficiency in these pa-
tients. In addition, because vitamin B6 is water
soluble, some of this vitamin is probably removed
during peritoneal dialysis and hemodialysis.
In renal failure, there may also be inhibitors of
vitamin B6 that could interfere with the vitamin B6
assays. Indeed, it is theoretically possible that such
inhibitors may alter the tests for vitamin B6 defi-
ciency without causing a true metabolic abnormal-
ity. But, because evidence for vitamin B6 deficiency
has been obtained by microbiologic assay [1] as well
as by several biochemical assays [2—8], this seems
unlikely. Moreover, vitamin B6 supplements when
given in large doses have been shown to improve
certain physiologic or biochemical phenomena in
patients with renal failure. Thus, Dobblestein et al
report that in hemodialysis patients pyridoxine
hydrochloride, when given in doses of 300 mg/day,
improves lymphoblast transformation in mixed lym-
phocyte culture [3]. Kleiner et al were unable to
confirm improved lymphocyte blastogenesis with
pyridoxine administration [7]; but, lymphocyte
transformation was normal in their patients before
supplementation. These authors did find that with
pyridoxine supplementation, 300 mg/day, there was
a decrease in serum high-density lipoproteins and
an increase in plasma concentrations of several
amino acids that were low. It would be valuable to
ascertain whether the foregoing abnormalities will
also improve with 5 to 10 mg/day supplements of
pyridoxine hydrochloride.
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